Immunome Stock Gets EMA Review For Desmoid Tumor Drug

• Immunome reported that the European Medicines Agency validated its Marketing Authorization Application for varegacestat in desmoid tumors, supported by Phase 3 RINGSIDE data that met the primary and all key secondary endpoints.

• The new clinical readouts from ASCO and ESMO highlighted meaningful gains in symptom burden and physical function, which relate directly to varegacestat's potential real world impact for patients rather than only radiographic response.

• The focus now is on how Immunome's investment narrative could evolve as EMA validation of varegacestat directs attention to execution in desmoid tumors.

Scan how Immunome's desmoid tumor catalyst compares with other potential breakout stories across our hand-picked 19 high quality undiscovered gems set.

Immunome Investment Narrative Recap

To own Immunome, investors need to believe varegacestat can move from a late stage asset to a commercial product in desmoid tumors while an ADC and radioligand pipeline matures behind it. EMA validation keeps the European filing on track and leaves the FDA PDUFA action in April 2027 as the main near term regulatory catalyst and execution test.

The risks remain clear. Immunome has no product revenue today, is loss making and has relied on shareholder dilution. Any delay, label restriction or slower than expected uptake for varegacestat would likely keep the business dependent on external funding while it carries several early stage programs in parallel.

The EMA validation ties directly into the earlier FDA acceptance of Immunome's NDA for varegacestat in desmoid tumors. Together, these form a coordinated regulatory path in the US and Europe. With progression free survival, objective response rate and patient reported outcomes already presented, the operational focus now is on preparing for a potential launch while continuing to follow patients in the open label extension.

In that context, the ESMO patient reported outcome data appear operationally relevant rather than purely academic. Symptom scores and physical function measures help define the real world value story that Immunome will need to present to desmoid tumor specialists, who have historically relied on active surveillance. Investor attention is likely to remain on how effectively the company translates those data into physician education, access work and, if approved, prescription habits.

Immunome's narrative projects US$306.2 million revenue and US$52.8 million earnings by 2029. This implies yearly revenue growth from a zero base and an earnings increase of about US$307.1 million from a current loss of US$254.3 million.